Fujirebio was founded in Tokyo, Japan in 1950 under the name Fujizoki Pharmaceutical, Co., Inc. In its early days the company developed and manufactured pharmaceutical products. The company's first IVD test was launched in 1966, a TPHA kit for syphilis testing. In 1983 the company changed name to Fujirebio Inc. Between 1998 and 2010 Fujirebio acquired several specialized IVD companies, notably Centocor Diagnostics (1998), CanAg Diagnostics (2006) and Innogenetics (2010). In 2005, Fujirebio Inc. was integrated together with the commercial laboratories
SRL, Inc. ("Special Reference Laboratories", established in 1970) under the holding company Miraca Holdings Inc. (which was renamed to
H.U. Group Holdings, Inc. in 2020). The current company structure, Fujirebio Holdings, Inc. was created in 2017 as a parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. In 2022, Fujirebio acquired respectively the companies ADx NeuroSciences and Fluxus, Inc. In 2025, Fujirebio acquired Plasma Services Group, Inc. • 1950: Fujirebio (formerly Fujizoki Pharmaceutical, Co., Inc.) is founded in Tokyo, Japan. • 1966: Launch of HA Ag (TPHA), the world's first
hemagglutination test for
syphilis. • 1981: Established Fujirebio Taiwan Inc. • 1987: Established Fujirebio America, Inc. (merged to Fujirebio Diagnostics, Inc.) in the United States. • 1998: Acquisition of Centocor Diagnostics of Pennsylvania, Inc. (USA, currently Fujirebio Diagnostics, Inc.), pioneer in
oncology testing and developer of CA125II,
CA19-9 and
CA15-3. • 2006: Acquisition of CanAg Diagnostics AB (Sweden, currently Fujirebio Diagnostics AB), leader in oncology biomarker development. • 2007: Launch of CL4800 in Japan to support blood
screening for the
Japanese Red Cross Society (~2019). • 2008: Acquisition of Advanced Life Science Institute, Inc. • 2008: Acquisition of American Biological Technologies, Inc. (merged to Fujirebio Diagnostics, Inc.). • 2010: Acquisition of
Innogenetics N.V. (Belgium, currently Fujirebio Europe N.V.), world leader in specialty
molecular and
immunoassay testing. • 2017: Established Fujirebio Holdings, Inc., as parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. • 2019: Established Fujirebio Diagnostics Japan, Inc., focusing on OEM business in Japan. • 2020: Established Fujirebio China Co., Ltd. • 2022: Acquisition of ADx NeuroSciences. • 2022: Acquisition of Fluxus, Inc. • 2025: Acquisition of Plasma Services Group, Inc. ==References==